ANI Pharmaceuticals Q1 revenue rises 20.5% to $237.5 million; raises 2026 guidance
ANI Pharmaceuticals reported first quarter 2026 revenue of $237.5 million, up 20.5% from a year earlier, and GAAP net income of $29.5 million, or $1.28 per diluted share, compared with $0.69 a year earlier. The company raised its 2026 total net revenue, adjusted EBITDA and adjusted diluted EPS guidance and authorized a $100 million share repurchase program.
Key points
- Q1 2026 total net revenues of $237.5 million, up 20.5%; Cortrophin Gel net revenues of $75.1 million, up 42.1%
- GAAP diluted EPS of $1.28 vs. $0.69 a year earlier; adjusted non-GAAP diluted EPS of $2.05 vs. $1.70
- 2026 total net revenue guidance raised to $1,080 million to $1,140 million from $1,055 million to $1,115 million; adjusted non-GAAP EBITDA raised to $285 million to $300 million
- Board authorized a $100 million share repurchase program effective May 8, 2026, running through May 2029; Brands net revenues fell 50.9%
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:58 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 08, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.